Genesis Biotechnology Acquires STATKING Clinical Services

Genesis Biotechnology Group (GBG) and its CRO arm Genesis Drug Discovery & Development (GD3), has acquired the STATKING Clinical Services, a provider of clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products.

"We are very pleased to have STATKING join GBG, and this acquisition demonstrates our commitment to making GD3 a fully integrated concept to commercialization CRO," said Eli Mordechai, Ph.D., CEO of GBG. "STATKING's acquisition strengthens our services and strategic presence throughout the life cycle of the drug development process. STATKING has achieved significant milestones in its 30 years of service, and I look forward to an exciting future together."

"STATKING and GD3 share a common vision that delivering better therapies to patients faster requires an integration of drug discovery and clinical trial services," said Rod Lashley. The addition of STATKING's clinical services to GD3's integrated, early-late stage drug discovery solutions will create a unique platform for clients to work with one scientific partner to enhance the speed and efficiency with which they can advance their therapies into the clinics.